Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture protocol
Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture protocol; bounded primary-source candidate.
Overview
Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture protocol; bounded primary-source candidate.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
1 recorded evaluation, 1 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.
Results
Results are available, but no reviewed comparison panel is linked in this release.
All evaluations
1 evaluation · 1 result. Different protocols are not a single leaderboard.
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture configuration | Protocol: Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture protocol Dataset: Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture dataset | 93.7% positive_percent_agreement_initial_blood_culture percent · higher Uncertainty: 95% CI 84.5–98.2% Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceKarius 2019 plasma microbial cfDNA positive agreement with initial blood culture evaluation amp-20261007-dna-pathogens-protocol Aggregation: Not reported Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture source · Blauwkamp et al. primary article Table 2, PDF page 7, Positive by initial blood culture row: NGS positive 59, NGS negative 4, Agreement 93.7%, 95% CI 84.5–98.2%. Results clinical-validation subsection calls this sensitivity. |
Source checking is not independent reproduction. Release 2026-10-07-1448159e6a81.
Methods and evaluation design
Procedure, tasks and evaluated configurations
Recorded evaluations
Each evaluation records what was tested and under which conditions.
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.
- Author-reported evaluations
- 1
Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.
Null control
Proposed control: requires review
Protocol-valid abundance or assignment control
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Conventional reference
Proposed control: requires review
Conventional reference-database method with pinned taxonomy/database
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Protocol coverage CSV · Model evaluation matrix · Source table · Release and checksums
Coverage is derived from release 2026-10-07-1448159e6a81. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run instructions
No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Strengths, limitations and unresolved questions
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
View linked audit checks and correction history
Release 2026-10-07-1448159e6a81 · Record review: source checked
1 source records and release history
- Karius 2019 plasma microbial cfDNA positive agreement with initial blood culture source · Original source · Blauwkamp et al., Nature Microbiology 4, 663–674 (2019)
Technical metadata and extraction receipts
Stable ID: amp-20261007-dna-pathogens-protocol
- areas
- dna-genomes
- method types
- conventional_pipeline
- tasks
- pathogen_detection
- missing metadata
- version: No immutable protocol identifier extracted
- scope note
- Positive agreement uses initial blood culture as reference, which does not identify all infections. It is not sensitivity against all true infections. Exact executable/software/database revision is not established; no foundation model and no new execution. Composite-reference outcomes and estimates are separate endpoints; Table 2 negative composite CI54.8–70.0 conflicts with narrative55.2–70.4 and is excluded. DNA-only plasma microbial cfDNA assay; no RNA viral detection or RNA sensitivity implied. Primary article hosted on third-party rious168 mirror; DOI/title match publisher. Public redistribution licence absent; only compact factual table excerpt retained, original PDF retrieval hash preserved.
- source locator
- Blauwkamp et al. primary article Table 2, PDF page 7, Positive by initial blood culture row: NGS positive 59, NGS negative 4, Agreement 93.7%, 95% CI 84.5–98.2%. Results clinical-validation subsection calls this sensitivity.
- task
- positive_percent_agreement_initial_blood_culture
- version
- Not reported
- workflow
- Karius 2019 plasma microbial cfDNA sequencing test; custom taxonomic analysis and contamination filtering; 1,250 reportable organisms. DNA only; excludes RNA viral detection.